Clinical trial

Neoadjuvant SBRT and Tislelizumab (Immunotherapy) Plus Anlotinib for Resectable EGFR Wild-type NSCLC

NCT07231575

Drugs and interventions used in this trial

3 registered

These interventions are listed by ClinicalTrials.gov. An RxNorm link indicates a mapped medicine record; the registry name alone is not proof of a specific branded formulation.

Search this trial's interventions

RADIATION · Unmapped registry intervention SBRT Find medicine records · Find other trials using this name

DRUG · Unmapped registry intervention Immunotherapy Find medicine records · Find other trials using this name

DRUG · Unmapped registry intervention antiangiogenesis therapy Find medicine records · Find other trials using this name

Study at a glance

Registry-backed

Neoadjuvant SBRT and Tislelizumab (Immunotherapy) Plus Anlotinib for Resectable EGFR Wild-type NSCLC

Design: INTERVENTIONAL · Status: NOT YET RECRUITING · Phase: PHASE2

Read study objectives, eligibility and outcome measures at ClinicalTrials.gov

StatusNOT_YET_RECRUITING

Study typeINTERVENTIONAL

Start date2025-11-10

PhasePHASE2

Conditions

Neoadjuvant Immunotherapyunresolved

NSCLCverified · MONDO: non-small cell lung carcinoma

Chemo-free Therapyunresolved

Interventions

SBRTRADIATION

ImmunotherapyDRUG

antiangiogenesis therapyDRUG

Sponsors & collaborators

Sun Yat-sen Universitylead sponsor

Registry source

Open the source record to verify current eligibility, contacts, locations and registry updates.

Open NCT07231575 on ClinicalTrials.gov ↗

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.